GLP-1 Compounding: When Innovation May Mean Liability

As previously reported on our blog, the rise of compounded GLP-1 medications has sparked both excitement and concern across the healthcare and legal landscapes. As demand for weight-loss treatments increases, some pharmacies have begun offering compounded versions of popular drugs like semaglutide and tirzepatide.
Read More
Disappointing GLP-1 Results in Alzheimer’s Trial: Underscores Promise (and Limits) of Single-Agent Approaches

Scientists have studied Alzheimer’s disease for over a century, since Alois Alzheimer’s initial description of brain abnormalities in a patient with presenile dementia. Today, amyloid‑beta plaques and tau tangles are recognized as hallmarks of the disease, though its causes are complex and multifactorial.
Read More
Opens in new tab Opens email app